Enrolled patients had clinically high-risk atherosclerotic vascular disease, with 90% having coronary artery disease, 22% a history of stroke, and 69% diabetes of $5 years' duration. They were also treated with standard-of-care medications for cardiovascular disease and diabetes: 95% were on antiplatelet agents, 98% were on a statin, and 73% were on an angiotensinconverting enzyme inhibitor; 63% had a glycosylated hemoglobin #7%, and the average hsCRP was 1.8 mg/l.
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The problem is that aggressive standard therapies may have made it difficult to demonstrate effectiveness of incremental therapy with canakinumab.
It is unclear in the current study how many subjects had carotid lesions with advanced plaque features, such as a lipid-rich necrotic core (LRNC). 
